title: Natural product discovery: past, present, and future.
abstract: Microorganisms have provided abundant sources of natural products which have been developed as commercial products for human medicine, animal health, and plant crop protection. In the early years of natural product discovery from microorganisms (The Golden Age), new antibiotics were found with relative ease from low-throughput fermentation and whole cell screening methods. Later, molecular genetic and medicinal chemistry approaches were applied to modify and improve the activities of important chemical scaffolds, and more sophisticated screening methods were directed at target disease states. In the 1990s, the pharmaceutical industry moved to high-throughput screening of synthetic chemical libraries against many potential therapeutic targets, including new targets identified from the human genome sequencing project, largely to the exclusion of natural products, and discovery rates dropped dramatically. Nonetheless, natural products continued to provide key scaffolds for drug development. In the current millennium, it was discovered from genome sequencing that microbes with large genomes have the capacity to produce about ten times as many secondary metabolites as was previously recognized. Indeed, the most gifted actinomycetes have the capacity to produce around 30-50 secondary metabolites. With the precipitous drop in cost for genome sequencing, it is now feasible to sequence thousands of actinomycete genomes to identify the "biosynthetic dark matter" as sources for the discovery of new and novel secondary metabolites. Advances in bioinformatics, mass spectrometry, proteomics, transcriptomics, metabolomics and gene expression are driving the new field of microbial genome mining for applications in natural product discovery and development.
authors.affiliation: Synthetic Biology Engineering Research Center, University of California-Berkeley, 5885 Hollis St. 4th Floor, Emeryville, CA, 94608, USA.
authors.forename: Leonard
authors.initials: L
authors.lastname: Katz
authors.affiliation: CognoGen Biotechnology Consulting, 7636 Andora Drive, Sarasota, FL, 34238, USA. rbaltz923@gmail.com.
authors.forename: Richard H
authors.initials: RH
authors.lastname: Baltz
mesh_terms: D039903:Actinobacteria / Q000235:genetics / Q000378:metabolism; D000818:Animals; D000900:Anti-Bacterial Agents / Q000302:isolation & purification / Q000378:metabolism; D001688:Biological Products / Q000737:chemistry / Q000266:history / Q000302:isolation & purification*; D019295:Computational Biology / Q000266:history / Q000379:methods / Q000639:trends; D055808:Drug Discovery / Q000266:history* / Q000379:methods / Q000639:trends*; D004345:Drug Industry / Q000266:history / Q000379:methods / Q000639:trends; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D064210:Secondary Metabolism
chemical_list: D000900:Anti-Bacterial Agents; D001688:Biological Products
keywords: Actinomycete; Antibiotic; Discovery; Fungi; Genome mining; Natural product; Secondary metabolite; Streptomyces